Drug Trial Radar · NCT04812262
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Feb 24, 2021
Primary completion
Dec 20, 2022
Study completion Feb 14, 2023
Sponsor
- Lead sponsor
- Neuraly, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). The study will be conducted in 2 Parts (Part A and B), with up to 8 cohorts included in each part (Part A; Cohorts A1 to A8 and Part B; Cohorts B2 to B8).
Conditions
- Overweight and Obesity
- Type2 Diabetes
- NAFLD
Interventions
DD01Drug
The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
PlaceboDrug
Placebo drug of DD01, administered in a 1mL volume for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events and serious adverse eventsTime frame: Part A - 43 days
- Number of participants with treatment-related adverse events and serious adverse events (TEAEs)Time frame: Part B - 57 days
- Number of participants with clinically significant abnormalities in clinical laboratory valuesTime frame: Part A - 43 days
- Number of participants with clinically significant abnormalities in clinical laboratory valuesTime frame: Part B - 57 days
- Number of participants with clinically significant abnormalities in physical examinationsTime frame: Part A - 43 days
- Number of participants with clinically significant abnormalities in physical examinationsTime frame: Part B - 57 days
- Number of participants with clinically significant abnormalities in vital signsTime frame: Part A - 43 days
- Number of participants with clinically significant abnormalities in vital signsTime frame: Part B - 57 days
- Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM)Time frame: Part A - 43 days
- Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM)Time frame: Part B - 57 days
- Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader)Time frame: Part A - 43 days
- Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader)Time frame: Part B - 57 days
- Number of participants with clinically significant abnormalities in 12-lead ECGsTime frame: Part A - 43 days
- Number of participants with clinically significant abnormalities in 12-lead ECGsTime frame: Part B - 57 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Prosciento
Chula Vista, California
Southwest General Healthcare Center
Fort Myers, Florida
Combined Research Orlando
Orlando, Florida
FDI Clinical Research
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.